AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study

AbbVie's (ABBV) phase III VERONA study of Venclexta plus azacitidine in higher-risk myelodysplastic syndrome (MDS) failed to meet its primary endpoint of overall survival, showing a hazard ratio of 0.908 compared to azacitidine plus placebo. This is another setback for Venclexta, which had $665 million in sales in Q1 2025, although AbbVie states that this failure does not impact currently approved indications for the drug. Despite this, AbbVie is continuing to expand its oncology pipeline, which now includes five marketed therapies.

Analysis

AbbVie (ABBV) has reported a significant clinical setback with its blockbuster cancer drug Venclexta. The phase III VERONA study, evaluating Venclexta in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome (MDS), failed to meet its primary endpoint of overall survival. The results indicated a hazard ratio of 0.908, demonstrating no statistically significant improvement in survival compared to azacitidine plus placebo. This follows a previous late-stage trial failure for Venclexta in 2023, where it did not meet the primary endpoint of progression-free survival in certain multiple myeloma patients. Despite these R&D disappointments which may temper expectations for Venclexta's label expansion, AbbVie has affirmed that these outcomes do not affect the drug's currently approved indications for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Venclexta remains a key revenue contributor, generating $665 million in sales during the first three months of 2025, a 12% year-over-year increase, driven by strong demand in its existing markets. AbbVie's broader oncology strategy involves diversification, evidenced by its portfolio of five marketed therapies including Epkinly and Elahere, and a pipeline featuring late-stage assets like etentamig and Temab-A. Year-to-date, ABBV shares have risen 8%, outperforming the industry's 3% growth, suggesting investor confidence may be supported by the existing product strength and pipeline diversity despite specific trial setbacks.

Key Decisions for Investors

• Investors should recognize that the VERONA study failure limits Venclexta's potential expansion into higher-risk MDS, potentially capping a future growth avenue for this specific drug.
• Monitor the full data presentation from the VERONA study, as nuanced findings could provide further insight into Venclexta's activity or specific patient subpopulations.
• Focus on AbbVie's progress with its diversified oncology pipeline, particularly late-stage assets like etentamig and Temab-A, as successes here will be crucial for sustained long-term growth in oncology and to mitigate the impact of Venclexta's recent trial results.
• Evaluate AbbVie's current valuation by balancing the continued strong commercial performance of Venclexta in its approved indications and the overall pipeline potential against the risks highlighted by recent clinical trial disappointments.